BRAF and neoplasm: Therapeutic approaches to overcome increased tumor cell survival include the combination of histone deacetylases (HDAC) and MAPK inhibition, selective BRAF inhibitors (e.g., vemurafenib or dabrafenib), MEK1/2 pathway inhibition (trametinib) or a BRAF/MEK inhibitors combination in patients with confirmed mutations (62).